Ortho Clinical Diagnostics Holdings PLC Stock News

OCDX earnings call for the period ending December 31, 2021.

Ortho Clinical Diagnostics Holdings PLC (OCDX) CEO Christopher Smith on Q4 2021 Results - Earnings Call Transcript

Ortho Clinical Diagnostics press release (OCDX): Q4 Non-GAAP EPS of $0.18 beats by $0.03.Revenue of $521M (+0.9% Y/Y) misses by $4.26M.

Strong Revenue Growth Drives Financial Results Strong Revenue Growth Drives Financial Results

Ortho Clinical (OCDX) delivered earnings and revenue surprises of 20% and 0.39%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Technology stocks had a lousy start to 2022. QQQ lost 9% of its value in January. Pandemic winners are getting crushed while energy stocks are surging.

NEW YORK , Dec. 23, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Ortho Clinical Diagnostics Holdings plc ("Ortho" or the "Company") (NASDAQ: OCDX ), in connection with the proposed acquisition of the Company by Quidel Corporation ("Quidel") (NASDAQ: QDEL ). Under the terms of the merger agreement, the Company''s shareholders will receive $7.14 in cash and 0.1055 shares of common stock in the combined company for each Ortho common share they own, representing implied per-share merger consideration of approximately $24.68 based upon Quidel''s December 22, 2021 closing price of $166.24 . Upon completion of the transaction, Ortho shareholders are expected to own approximately 38% of the combined company. The transaction is valued at approximately $6.0 billion . Full story available on Benzinga.com

NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by Quidel Corporation (NASDAQ: QDEL).

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) to Qu

Quidel will acquire Ortho Clinical Diagnostics Holdings PLC in a billion-dollar deal

Quidel will acquire OCDX stock for $24.68 per share and newly issued stock. The transaction will be worth a total of $6 billion.